Genexa is the world’s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don’t. It’s medicine made clean, because that’s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything

Hoopsy started in December 2021, to date we have a product, and approval to sell in Europe and UK. We launched into the UK in mid-July. Our first product is The Hoopsy Eco Pregnancy Test a 99% plastic-free test made from 99% paper. with over 99% accuracy (same as leading brands). We have bigger plans than just pregnancy tests, we want to eliminate plastic from home based test kits and have a plan to do that!

We enable our customers to create data-driven insights out of shared datasets, without actually sharing any sensitive data, and staying in full control over your own data. How? Through the cryptographic magic of secure multi-party computation (MPC) and blockchain technology. Interested what we can do for you? Please send us a message.

We are Altano Capital and as founders, we have been involved in the investment scene since 2000. Our goal is to find promising life-science companies and talented entrepreneurs with the potential to change the healthcare industry.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

WE Life Sciences fund life sciences entrepreneurs. It is a subsidary of WE International.

Founded by a nurse, Intulect is transforming clinical education by making high-fidelity simulation scalable and accessible. Our AI-facilitated platform empowers educators to run hundreds of realistic, competency-based simulations at once—no extra faculty required. Intulect is where training becomes instinct.

A fitness app that is especially designed for the disability community. Bringing access to exercise for varying impairments not seen previously. We aim to empower, guide, and educate disabled peoples journey into living a healthier and fitter life by making informed decisions based on their impairment and giving them more access to exercise.

We are an International Corporate Finance advisory firm based in Barcelona and Madrid with a focus on M&A, Private Equity Advisory, Financial & Strategic Advisory and Financing Our purpose: We are in the finance industry to put people first, make it transparent, accessible and trustworthy. Our Mission: To support the visionaries who want to change the world to make it a more ethical, sustainable and people-driven planet to live in. Our Vision: To become the fastest growing corporate finance advisors focused on disruptive businesses, new talents and entrepreneurs.

Imagine a world where you are no longer managed by your chronic pain. 20% of the world's population suffer from chronic pain every day. Unlike other medical conditions (heart problems for example) there are no objective tools for measuring pain. There are numerous cases where there is no physical evidence to the source of the pain. This Subjective process makes it hard for both the patients and healthcare professionals Equanimity AI aims to solve this complex problem by using the principles of the Biopsychosocial model. By using continuous monitoring and cutting-edge AI system, Equanimity AI will revolutionize the domain of chronic pain for both patients and healthcare professionals. Making the first step towards change is often the hardest thing to do. Equanimity AI, with its experienced team, the right tools and knowledge can make this dream come true. Discover what we can do for you today.

Convergence Partners is a pan-African tech focused private equity player, delivering enhanced investment returns while underpinning Continental development. We have a proven track record of developing new investment opportunities as well as active adding value to investments across the lifecycle of tech assets. As impact investors, Convergence Partners brings its skills, experience and capital to accelerate ICT infrastructure development in Africa, focusing on initiatives that increase availability of communications, broadband services and new technology offerings to the people of Africa

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.

Impli is a pioneering biotechnology company dedicated to revolutionizing accessibility and efficacy in the world of in vitro fertilization (IVF). Our breakthrough innovation, a biosensing platform, a novel combination of electronics and subdermal biosensors, allows for the continuous monitoring of hormones crucial for egg retrieval, embryo transfer, and pregnancy development. Leveraging NFC technology, the device communicates seamlessly with modern smartphones, providing instant readings of three vital hormone levels. This capability eliminates the need for frequent blood draws, offering a convenient and accurate approach to enhancing IVF outcomes. Founded in April 2019, Impli was conceived with a mission to improve lives through cutting-edge implantable technology. Our inaugural product, ImpliCaspian, set the standard by enabling users to store and access medical information effortlessly via a smartphone app. Since then, our vision has evolved, focusing on the future of biosensors and the development of innovative products that provide real-time, hassle-free access to personal health data at the touch of a phone. The promise of our technology heralds a transformative era for IVF, with the potential to make it more accessible, reduce the number of required cycles, and significantly increase successful pregnancy rates. Our advancements have garnered recognition, including a feature in the Octopus Ventures Future of Fertility Report. At Impli, we are committed to shaping a healthier and safer world through the power of biotechnology one IVF journey at a time.

We are shaping the future of medicine through the power of data analysis

Growth debt for scale-up businesses. Take your next step to growth with Bootstrap Europe. We provide progressive, ambitious entrepreneurs and shareholders with non-dilutive funding to help them succeed.

Millions of people live with wounds that won’t heal. These wounds limit mobility, cause pain, and take away independence. Current treatments are often slow, expensive, and frustrating — for patients, caregivers, and healthcare systems alike. At Plasmacure, we’re changing that. Our patented cold plasma system, PLASOMA, is the first solution proven to close chronic wounds faster, safer, and more effectively. Clinically validated In a randomized controlled trial, PLASOMA was shown to be 2.5x more effective than traditional wound care. Cuts costs, boosts efficiency Treatment with PLASOMA can reduce healthcare costs by more than 40% and free up clinicians’ time by more than 50%. Fast and easy Each session takes just two minutes and fits easily into existing care routines. Safe in clinic and at home PLASOMA is currently the only cold plasma wound care solution proven safe and effective for both in-clinic and home use, validated through a peer-reviewed RCT. With a CE-marked Class IIb medical device already on the market, we are expanding across Europe and preparing entry into the United States and China.

We are a venture capital firm that invests in the best impact startups.

youth.gov was created by the Interagency Working Group on Youth Programs (IWGYP), which is composed of representatives from 25 federal departments and agencies that support programs and services focusing on youth. The IWGYP promotes the goal of positive, healthy outcomes for youth.

TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Bioscience Equity Partners (BEP), a leading global investment bank, fund and fund manager exclusive to the life sciences sector. At BEP, we not only manage funds for prominent sovereign wealth funds in the Middle East and leading corporate venture capital entities solely focused on early stage life science companies , but we also own and operate our own fund Antisoma. Our primary focus is providing venture capital, equity, and debt financing, tailored to accelerate growth and innovation. In addition to venture capital, BEP is highly active in mergers and acquisitions (M&A), offering funding, advice and strategic support throughout the transaction process. Our strategic collaborations with global giants reinforce our position as a trusted partner in navigating the complexities of the bioscience industry.

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint